In response to public comment on draft recommendations published last year, the USPSTF changed course and retained cotesting as an option.
Efforts are underway to standardize pharmacogenetic testing, but experts say more needs to be done to encourage broader acceptance of these recommendations.
A number of consumer genetic testing companies are adopting best practice guidelines for customer privacy, the Washington Post reports.
A panel led by the FH Foundation recommends routine genetic testing for those with very high LDL cholesterol and a family history of high cholesterol or early heart attack.
As the National Guideline Clearinghouse goes dark, the ECRI Institute says it will pick up the slack.
The updated recommendations discuss testing for DNA repair gene mutations, MSI-H, and dMMR, as well as germline testing and counseling.
The guidelines are the first to attempt to specify which drugs are appropriate to test for routinely, guideline authors say.
With only one test FDA-approved for primary hrHPV screening, groups express concern about feasibility of moving away from co-testing
The changes include recommendations for first line immunotherapy in patients with high PD-L1 expression, and clarification on use of targeted therapies.
Agendia said that the guidelines reflect MammaPrint's rank as the only multigene test to receive level 1A status, based on prospective, randomized data from the MINDACT clinical trial.
The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.
Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.
In Science this week: in vitro generation of human reproductive cells, and more.
Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.